Short answer
Relay Therapeutics, Inc. (RLAY) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Relay Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $0, net loss $81.7M, or $0.37 per share, reflecting continued clinical-stage cash burn
- Cash, equivalents and investments $848.6M, up from $554.5M at year-end, with funding expected into 2029
- ReDiscover-2 Phase 3 enrollment targeted for mid-2027, approximately one year faster than recent benchmarks
- ASH 2026 oral presentation and regulatory update could materially clarify zovegalisib’s vascular-anomalies path
- New mutant-selective TIE2 inhibitor expands pipeline, targeting an estimated 50,000-60,000 U.S. patients with TIE2-mutated malformations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Relay Therapeutics, Inc. 8-K filings
Get the next RLAY 8-K as it lands
Follow RLAY for push alerts, or ask the research agent what this filing means.